

# Patrick D W Kiely

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6267390/publications.pdf>

Version: 2024-02-01

79  
papers

2,804  
citations

249298  
26  
h-index

206121  
51  
g-index

79  
all docs

79  
docs citations

79  
times ranked

3784  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 65-73.	0.5	24
2	Large joints are progressively involved in rheumatoid arthritis irrespective of rheumatoid factor status—results from the early rheumatoid arthritis study. <i>Rheumatology International</i> , 2022, 42, 621-629.	1.5	3
3	Rituximab and intravenous immunoglobulin treatment in PM/Scl antibody-associated disease: case-based review. <i>Rheumatology International</i> , 2022, 42, 359-364.	1.5	2
4	Management of rheumatoid arthritis. <i>Medicine</i> , 2022, , .	0.2	0
5	Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case series. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 298-303.	0.4	1
6	Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 4687-4701.	0.9	5
7	British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2022, 61, 1760-1768.	0.9	37
8	Fatigue in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Network. <i>Rheumatology</i> , 2022, 61, 3737-3745.	0.9	5
9	Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case series.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 298-303.	0.4	0
10	The Utility of Myositis Specific Antibodies in Clinical Practice. <i>journal of applied laboratory medicine</i> , The, 2022, 7, 1189-1201.	0.6	3
11	P192—Efficacy of filgotinib in rheumatoid arthritis by age, body weight, body mass index: post hoc subgroup analysis of two phase 3 trials. <i>Rheumatology</i> , 2022, 61, .	0.9	0
12	Ankle arthritis — an important signpost in rheumatologic practice. <i>Rheumatology</i> , 2021, 60, 23-33.	0.9	13
13	Disease—impact of rheumatoid arthritis in patients not treated with advanced therapies; survey findings from the National Rheumatoid Arthritis Society. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa080.	0.3	5
14	Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients. <i>Rheumatology</i> , 2021, 60, 5233-5238.	0.9	15
15	P152—The incidence of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies may be higher than we think. <i>Rheumatology</i> , 2021, 60, .	0.9	0
16	Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network. <i>Rheumatology</i> , 2020, 59, 1272-1280.	0.9	17
17	Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 2381-2391.	0.9	10
18	Use of rheumatoid arthritis impact of disease (RAID) in routine care; identification of DAS28 remission and unmet patient-reported outcomes. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa013.	0.3	21

#	ARTICLE	IF	CITATIONS
19	What do UK Rheumatologists do when the patient doesn't fit the guideline for treatment?. <i>Rheumatology</i> , 2020, 59, 1465-1466.	0.9	1
20	Unexpected Troponin Elevation in a Patient Treated with Atorvastatin. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 798-801.	0.6	5
21	Are the elderly with rheumatoid arthritis treated less aggressively? Findings from an inception cohort. <i>Rheumatology</i> , 2019, 58, .	0.9	2
22	The long-term progression of disease activity, functional disability and quality of life using data from two early RA cohorts. <i>Rheumatology</i> , 2019, 58, .	0.9	0
23	Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. <i>BMJ Open</i> , 2019, 9, e028466.	0.8	140
24	Delays between the onset of symptoms and first rheumatology consultation in patients with rheumatoid arthritis in the UK: an observational study. <i>BMJ Open</i> , 2019, 9, e024361.	0.8	43
25	Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz002.	0.3	9
26	Biologic treatments for rheumatoid arthritis. <i>Trends in Urology &amp; Men's Health</i> , 2019, 10, 13-17.	0.2	0
27	Disease activity flares and pain flares in an early rheumatoid arthritis inception cohort; characteristics, antecedents and sequelae. <i>BMC Rheumatology</i> , 2019, 3, 49.	0.6	11
28	Discrete Trajectories of Resolving and Persistent Pain in People With Rheumatoid Arthritis Despite Undergoing Treatment for Inflammation: Results From Three UK Cohorts. <i>Journal of Pain</i> , 2019, 20, 716-727.	0.7	19
29	Management of rheumatoid arthritis. <i>Medicine</i> , 2018, 46, 216-221.	0.2	12
30	The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network UK prospective cohorts. <i>Rheumatology</i> , 2018, 57, 1194-1202.	0.9	53
31	Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial. <i>Rheumatology</i> , 2018, 57, 84-91.	0.9	17
32	Treating rheumatoid arthritis to target: is low disease activity good enough?. <i>Rheumatology</i> , 2018, 57, .	0.9	0
33	Validation of methods for converting the original Disease Activity Score (DAS) to the DAS28. <i>Rheumatology International</i> , 2018, 38, 2297-2305.	1.5	11
34	Pregabalin has efficacy for hand osteoarthritis pain: a proof-of-concept study using pain sensitisation measures. <i>Rheumatology</i> , 2018, 57, .	0.9	0
35	The successful use of subcutaneous abatacept in refractory anti-human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesophagopharyngeal disease. <i>Rheumatology</i> , 2018, 57, 1866-1867.	0.9	2
36	Interpretation of DAS28 and its components in the assessment of inflammatory and non-inflammatory aspects of rheumatoid arthritis. <i>BMC Rheumatology</i> , 2018, 2, 8.	0.6	28

#	ARTICLE	IF	CITATIONS
37	Immune Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. <i>Arthritis and Rheumatology</i> , 2017, 69, 1090-1099.	2.9	41
38	Can Rheumatologists Predict Eventual Need for Orthopaedic Intervention in Patients with Rheumatoid Arthritis? Results of a Systematic Review and Analysis of Two UK Inception Cohorts. <i>Current Rheumatology Reports</i> , 2017, 19, 12.	2.1	6
39	Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts. <i>Arthritis Care and Research</i> , 2017, 69, 1809-1817.	1.5	21
40	Medical arthroscopy: A tool for diagnosis and research in rheumatology. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 145-153.	0.9	11
41	Secular Changes in Clinical Features at Presentation of Rheumatoid Arthritis: Increase in Comorbidity But Improved Inflammatory States. <i>Arthritis Care and Research</i> , 2017, 69, 21-27.	1.5	61
42	Erosive and osteoarthritic structural progression in early rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 1477-1488.	0.9	18
43	Discordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data. <i>Arthritis Research and Therapy</i> , 2016, 18, 295.	1.6	22
44	Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2080-2086.	0.5	61
45	Biologic efficacy optimization—a step towards personalized medicine. <i>Rheumatology</i> , 2016, 55, 780-788.	0.9	38
46	The Effect of Disease Severity and Comorbidity on Length of Stay for Orthopedic Surgery in Rheumatoid Arthritis: Results from 2 UK Inception Cohorts, 1986–2012. <i>Journal of Rheumatology</i> , 2015, 42, 778-785.	1.0	10
47	The development and initial validation of a questionnaire to measure help-seeking behaviour in patients with new onset rheumatoid arthritis. <i>Health Expectations</i> , 2015, 18, 2340-2355.	1.1	7
48	General practitioners' perspectives on campaigns to promote rapid help-seeking behaviour at the onset of rheumatoid arthritis. <i>Scandinavian Journal of Primary Health Care</i> , 2014, 32, 37-43.	0.6	17
49	Hand and Foot Surgery Rates in Rheumatoid Arthritis Have Declined From 1986 to 2011, but Large Joint Replacement Rates Remain Unchanged: Results From Two UK Inception Cohorts. <i>Arthritis and Rheumatology</i> , 2014, 66, 1081-1089.	2.9	101
50	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 328-335.	0.5	222
51	Prediction of Future Pain by Das28-P in Patients With Early Rheumatoid Arthritis: The Eran Cohort. <i>Rheumatology</i> , 2014, 53, i71-i72.	0.9	0
52	Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 153.	0.8	11
53	Interstitial Lung Disease in Inflammatory Myopathies: Clinical Phenotypes and Prognosis. <i>Current Rheumatology Reports</i> , 2013, 15, 359.	2.1	44
54	Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. <i>Rheumatology</i> , 2012, 51, 1870-1876.	0.9	33

#	ARTICLE	IF	CITATIONS
55	Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RA. <i>Rheumatology</i> , 2012, 51, 375-384.	0.9	57
56	Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisals. <i>Rheumatology</i> , 2012, 51, 24-31.	0.9	25
57	Remission in Early Rheumatoid Arthritis: Predicting Treatment Response. <i>Journal of Rheumatology</i> , 2012, 39, 470-475.	1.0	33
58	Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. <i>Rheumatology</i> , 2012, 51, 1416-1425.	0.9	71
59	Quantitative Sensory Testing in Painful Hand Osteoarthritis Demonstrates Features of Peripheral Sensitisation. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-8.	0.9	24
60	Rituximab Associated Pneumonitis in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2012, 18, 39-41.	0.5	10
61	Predictors of change in bodily pain in early rheumatoid arthritis: An inception cohort study. <i>Arthritis Care and Research</i> , 2012, 64, 1505-1513.	1.5	73
62	What makes osteoarthritis painful? The evidence for local and central pain processing. <i>Rheumatology</i> , 2011, 50, 2157-2165.	0.9	165
63	Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. <i>Rheumatology</i> , 2011, 50, 518-531.	0.9	198
64	Intra-articular infliximab in DMARD-resistant knee monoarthritis: clinical and ultrasound responses. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 231-239.	0.3	2
65	BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 2311-2313.	0.9	42
66	Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN). <i>Rheumatology</i> , 2011, 50, 926-931.	0.9	56
67	An evaluation of the strengths and weaknesses of a register of newly diagnosed rheumatoid arthritis, 1986-2010. <i>Rheumatology</i> , 2011, 50, 176-183.	0.9	20
68	Interrater reliability and aspects of validity of the myositis damage index. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1272-1276.	0.5	21
69	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. <i>Rheumatology</i> , 2010, 49, 1197-1199.	0.9	49
70	First-line DMARD choice in early rheumatoid arthritis--do prognostic factors play a role?. <i>Rheumatology</i> , 2010, 49, 1267-1271.	0.9	17
71	BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. <i>Rheumatology</i> , 2010, 49, 2217-2219.	0.9	187
72	The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. <i>Rheumatology</i> , 2010, 49, 295-307.	0.9	320

#	ARTICLE	IF	CITATIONS
73	Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. <i>Rheumatology</i> , 2009, 48, 765-772.	0.9	56
74	Reliability and validity of the myositis disease activity assessment tool. <i>Arthritis and Rheumatism</i> , 2008, 58, 3593-3599.	6.7	76
75	Devastating calcinosis in a patient with adult onset myositis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1005-1006.	0.9	3
76	Bowel associated dermatosis " arthritis syndrome: a case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 81.	0.4	16
77	Underestimation of Serum 25-Hydroxyvitamin D by the Nichols Advantage Assay in Patients Receiving Vitamin D Replacement Therapy. <i>Clinical Chemistry</i> , 2005, 51, 1072-1074.	1.5	17
78	The broadening use of leflunomide in clinical practice. <i>British Journal of Hospital Medicine</i> , 2004, 65, 735-739.	0.3	3
79	Oxpentifylline inhibits tumor necrosis factor- $\alpha$ mRNA transcription and protects against arthritis in mercuric chloride-treated Brown Norway rats. <i>European Journal of Immunology</i> , 1995, 25, 2899-2906.	1.6	25